OCUL R&D to Revenue
Ocular Therapeutix Inc · R&D to Revenue
OCUL R&D to Revenue
Latest reported401.77%period ending
OCUL Quarterly R&D/Revenue (0.00% → 401.77%)
Latest values, visible window
High-resolution chart · PNG
OCUL r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 401.7662% | |
| 613.936% | |
| 383.3962% | |
| 359.9972% | |
| 379.5304% | |
| 400.6076% | |
| 239.9543% | |
| 240.2204% | |
| 175.5185% | |
| 140.3479% | |
| 109.4183% | |
| 99.5889% | |
| 99.3942% | |
| 110.2662% | |
| 96.2202% | |
| 114.6594% | |
| 106.7993% | |
| 99.3403% | |
| 102.1937% | |
| 104.6573% | |
| 118.271% | |
| 148.8287% | |
| 103.742% | |
| 118.2948% | |
| 511.2173% | |
| 233.7294% | |
| 448.8032% | |
| 1,234.62% | |
| 1,448.3077% | |
| 2,300.2033% | |
| 2,035.3175% | |
| 1,944.7791% | |
| 1,349.537% | |
| 2,419.7059% | |
| 1,623.8193% | |
| 1,553.7285% | |
| 1,853.1963% | |
| 1,416.6316% | |
| 1,434.0509% | |
| 1,192.0335% | |
| 1,582.3129% | |
| 1,544.3231% | |
| 1,579.3578% | |
| 1,926.1072% | |
| 1,469.0632% | |
| 1,107.7465% | |
| 1,019.4059% | |
| 3,134.2657% | |
| 4,424.7423% | |
| 18,362.963% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |